Johnson Lab



About the lab

PI: Keith A. Johnson

The Johnson Lab focuses on imaging neurodegenerative disorders. More specifically, the lab is developing preventive therapies and treatment of Alzheimer’s disease. Recently the lab has been investigating imaging agents that can detect tau deposits in the brain related to cognitive impairment. The lab is exploring ways to use these imaging techniques to detect the risk of developing impairment.


Research

Members

Assistant in Physics/Instructor:
John Alex Becker

Research Fellow:
Heidi Jacobs

Clinical Research Coordinators:
Kelly Judge
Nicholas Andrea
John Bark
Danielle Cosio
Christopher Lee

Selected Publications

  • Quiroz YT, Sperling RA, Norton DJ, Baena A, Arboleda-Velasquez JF, Cosio D, Schultz A, Lapoint M, Guzman-Velez E, Miller JB, Kim LA, Chen K, Tariot PN, Lopera F, Reiman EM, Johnson KA. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurol 2018; ():
    View in: PubMed
  • Jacobs HIL, Hedden T, Schultz AP, Sepulcre J, Perea RD, Amariglio RE, Papp KV, Rentz DM, Sperling RA, Johnson KA. Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat. Neurosci. 2018; 21(3):424-431
    View in: PubMed
  • Sepulcre J, Grothe MJ, Sabuncu M, Chhatwal J, Schultz AP, Hanseeuw B, El Fakhri G, Sperling R, Johnson KA. Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. JAMA Neurol 2017; 74(7):813-820
    View in: PubMed
  • Sepulcre J, Sabuncu MR, Li Q, El Fakhri G, Sperling R, Johnson KA. Tau and amyloid β proteins distinctively associate to functional network changes in the aging brain. Alzheimers Dement 2017; 13(11):1261-1269
    View in: PubMed
  • Hanseeuw BJ, Betensky RA, Schultz AP, Papp KV, Mormino EC, Sepulcre J, Bark JS, Cosio DM, LaPoint M, Chhatwal JP, Rentz DM, Sperling RA, Johnson KA. Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. Ann. Neurol. 2017; 81(4):583-596
    View in: PubMed
  • Rentz DM, Mormino EC, Papp KV, Betensky RA, Sperling RA, Johnson KA. Cognitive resilience in clinical and preclinical Alzheimer’s disease: the Association of Amyloid and Tau Burden on cognitive performance. Brain Imaging Behav 2017; 11(2):383-390
    View in: PubMed
  • Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, Sperling R, Growdon JH, Dickerson BC, Johnson K. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA Neurol 2016; 73(11):1334-1341
    View in: PubMed
  • Chhatwal JP, Schultz AP, Marshall GA, Boot B, Gomez-Isla T, Dumurgier J, LaPoint M, Scherzer C, Roe AD, Hyman BT, Sperling RA, Johnson KA. Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. Neurology 2016; 87(9):920-6
    View in: PubMed
  • Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, Mormino E, Chhatwal J, Amariglio R, Papp K, Marshall G, Albers M, Mauro S, Pepin L, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson B, Gomez-Isla T, Hyman B, Vasdev N, Sperling R. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 2016; 79(1):110-9
    View in: PubMed
  • Hanseeuw BJ, Schultz AP, Betensky RA, Sperling RA, Johnson KA. Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. Alzheimers Dement 2016; 12(12):1288-1296
    View in: PubMed
  • Sepulcre J, Schultz AP, Sabuncu M, Gomez-Isla T, Chhatwal J, Becker A, Sperling R, Johnson KA. In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. J. Neurosci. 2016; 36(28):7364-74
    View in: PubMed
  • Maye JE, Betensky RA, Gidicsin CM, Locascio J, Becker JA, Pepin L, Carmasin J, Rentz DM, Marshall GA, Blacker D, Sperling RA, Johnson KA. Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. Neurobiol. Aging 2016; 40():61-67
    View in: PubMed
  • Greve DN, Salat DH, Bowen SL, Izquierdo-Garcia D, Schultz AP, Catana C, Becker JA, Svarer C, Knudsen GM, Sperling RA, Johnson KA. Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging. Neuroimage 2016; 132():334-343
    View in: PubMed
  • Gidicsin CM, Maye JE, Locascio JJ, Pepin LC, Philiossaint M, Becker JA, Younger AP, Dekhtyar M, Schultz AP, Amariglio RE, Marshall GA, Rentz DM, Hedden T, Sperling RA, Johnson KA. Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology 2015; 85(1):48-55
    View in: PubMed
  • Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer’s disease: implications for prevention trials. Neuron 2014; 84(3):608-22
    View in: PubMed
  • Sepulcre J, Sabuncu MR, Becker A, Sperling R, Johnson KA. In vivo characterization of the early states of the amyloid-beta network. Brain 2013; 136(Pt 7):2239-52
    View in: PubMed
  • Sperling RA, Karlawish J, Johnson KA. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 2013; 9(1):54-8
    View in: PubMed
  • Johnson KA, Sperling RA, Sepulcre J. Functional connectivity in Alzheimer’s disease: measurement and meaning. Biol. Psychiatry 2013; 74(5):318-9
    View in: PubMed
  • Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, Reiman EM, Sabbagh MN, Sadowsky CH, Fleisher AS, Murali Doraiswamy P, Carpenter AP, Clark CM, Joshi AD, Lu M, Grundman M, Mintun MA, Pontecorvo MJ, Skovronsky DM, . Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer’s disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013; 9(5 Suppl):S72-83
    View in: PubMed
  • Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH, , , . Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement 2013; 9(1):e-1-16
    View in: PubMed
  • Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. J. Nucl. Med. 2013; 54(3):476-90
    View in: PubMed
  • Sepulcre J, Sabuncu MR, Yeo TB, Liu H, Johnson KA. Stepwise connectivity of the modal cortex reveals the multimodal organization of the human brain. J. Neurosci. 2012; 32(31):10649-61
    View in: PubMed
  • Sepulcre J, Sabuncu MR, Johnson KA. Network assemblies in the functional brain. Curr. Opin. Neurol. 2012; 25(4):384-91
    View in: PubMed
  • Sperling RA, Johnson KA. Dementia: new criteria but no new treatments. Lancet Neurol 2012; 11(1):4-5
    View in: PubMed
  • Marshall GA, Olson LE, Frey MT, Maye J, Becker JA, Rentz DM, Sperling RA, Johnson KA. Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord 2011; 31(6):443-50
    View in: PubMed
  • Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-β associated cortical thinning in clinically normal elderly. Ann. Neurol. 2011; 69(6):1032-42
    View in: PubMed
  • Rentz DM, Locascio JJ, Becker JA, Moran EK, Eng E, Buckner RL, Sperling RA, Johnson KA. Cognition, reserve, and amyloid deposition in normal aging. Ann. Neurol. 2010; 67(3):353-64
    View in: PubMed

Open positions

Please contact us with questions or inquiries using the form below